Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Caroline Robert, Jean-Charles Soria, Alain Spatz, Axel Le Cesne, David Malka, Patricia Pautier, Janine Wechsler, Catherine Lhomme, Bernard Escudier, Valérie Boige, Jean-Pierre Armand, Thierry Le Chevalier

Journal: The Lancet. Oncology 2005;6(7):491-500

PMID: 15992698

Full Text on Elsevier Science View on PubMed

Abstract

Although kinase inhibitors raise hope for people with cancer, patients and their clinicians are commonly confronted with the cutaneous side-effects that are associated with the use of these drugs. This review is the result of collaborations between dermatologists, medical oncologists, and pathologists, and discusses the cutaneous side-effects seen after treatment with the inhibitors of epidermal-growth-factor receptor (EGFR), imatinib, sorafenib, and sunitinib. Some of the side-effects caused by these agents are very distressing, partly because they are chronic owing to the long duration of treatment. Therefore, patients need early and appropriate dermatological management. Moreover, several studies have reported a link between the antitumour efficacy of EGFR inhibitors and cutaneous side-effects. Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response.

Address: Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France. [email protected]

DOI: 10.1016/S1470-2045(05)70243-6

Link outs

Free resources

Medical:

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Miscellaneous:

https://assays.cancer.gov/CPTAC-802

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-EGFR-8

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1470...

MeSH Terms: Antibodies, Blocking, Antineoplastic Agents, Benzamides, Benzenesulfonates, ErbB Receptors, Hair Diseases, Humans, Imatinib Mesylate, Nail Diseases, Neoplasms, Niacinamide, Phenylurea Compounds, Piperazines, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Pyridines, Pyrimidines, Skin Diseases, Sorafenib